← FDA DRUG APPROVALS

FDA ANDA · ANDA205328

TESTOSTERONE

Sponsor: ACTAVIS LABS UT INC

APPLICATION
ANDA205328
TYPE
ANDA
ORIGINAL APPROVAL
2017-08-07
LATEST ACTION
2025-07-15
ROUTE
TOPICAL, TRANSDERMAL
DOSAGE FORM
SOLUTION, METERED
MARKETING STATUS
Prescription

Products

TESTOSTERONEPrescription
TESTOSTERONE 30MG/1.5ML ACTUATION · SOLUTION, METERED · TRANSDERMAL

Approval history

2025-07-15Labeling · Supplement 6 · standardAP
2019-06-11REMS · Supplement 2AP
2019-05-10Labeling · Supplement 1 · standardAP
2017-08-07UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →